NCT05163132

Brief Summary

The aim of this study is to correlate between quantitative results of shear wave elastography and CT picture in diffuse liver disease, including liver cirrhosis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 6, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 20, 2021

Completed
12 days until next milestone

Study Start

First participant enrolled

January 1, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2023

Completed
Last Updated

January 6, 2022

Status Verified

December 1, 2021

Enrollment Period

1 year

First QC Date

December 6, 2021

Last Update Submit

December 17, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Shearwave elastography (SWE) of the liver

    Analyze the correlation between SWE of liver and with computed tomography findings.

    1 week

Interventions

Shear wave elastography is an ultrasound applied technique used to measure tissue stiffness as a result of a disease. So, it can be used to evaluate liver stiffness as a result of liver cirrhosis

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients who diagnosed to had chronic liver diseases with or without present hepatic focal lesions.

You may qualify if:

  • Both sexes are included: patients who diagnosed to had chronic liver diseases with or without present hepatic focal lesions.

You may not qualify if:

  • Lactating and pregnant women
  • Patients known to had high serum creatinine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. Radiographics. 2009 Oct;29(6):1591-614. doi: 10.1148/rg.296095513.

  • Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015 Dec;44(4):717-34. doi: 10.1016/j.gtc.2015.07.003. Epub 2015 Aug 25.

  • Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and Management of Hepatitis C. Am Fam Physician. 2015 Jun 15;91(12):835-42.

  • Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012 Dec;56(6):2125-33. doi: 10.1002/hep.25936. Epub 2012 Aug 31.

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mohamed Abdeltawab, MD

    Assiut

    STUDY DIRECTOR
  • Hayam M Abd El-hakeem

    Assiut University

    PRINCIPAL INVESTIGATOR
  • Eman Abo El-hamd

    Assiut University

    STUDY CHAIR

Central Study Contacts

Mohamed Abdeltawab, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 6, 2021

First Posted

December 20, 2021

Study Start

January 1, 2022

Primary Completion

January 1, 2023

Study Completion

February 1, 2023

Last Updated

January 6, 2022

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share